SecBot SecBot
8-K ·Filed May 15, 2026

INDP

Indaptus Therapeutics, Inc.
BEARISH
Impact 7/10
Horizonimmediate Processed6mo ago SEC0001493152-26-023344
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The company faces imminent liquidity pressure and will likely need to raise capital in the near term, which would be highly dilutive given the $4M market cap. Traders should watch for any financing announcements, partnership deals, or strategic alternatives. The stock may also be at risk of delisting if it cannot meet Nasdaq continued listing standards.

DirectionBearish
Confidencehigh
Horizonimmediate

Price Chart

Loading chart...

Executive Summary

Indaptus Therapeutics reported Q1 2026 net loss of $2.5M ($0.23 loss per share) and ended the period with only $1.5M in cash, down from $8.5M at year-end 2025. Operating cash burn was $7.0M in the quarter, and the company explicitly states it will need additional capital to continue operations, with no assurance of financing. Combined with a management transition and a pause in clinical trial enrollment, the filing signals a severe near-term funding risk for this pre-revenue biotech.

Key Financial Metrics

EPS
−$0.23
Revenue
$0.00

Key Facts

  • Cash and cash equivalents fell from $8.5M (Dec 31, 2025) to $1.5M (Mar 31, 2026), a decline of $7.0M in one quarter.
  • Net cash used in operating activities was $7.0M for Q1 2026, compared to $5.0M in Q1 2025.
  • No financing activity occurred in Q1 2026, versus $3.2M raised in Q1 2025.
  • Net loss improved to $2.5M from $4.5M year-over-year, but loss per share fell from $9.11 to $0.23 due to a massive increase in weighted-average shares outstanding (10.96M vs 0.50M).
  • The company states it will need to raise additional capital and there can be no assurance such financing will be available.
  • Executive management transition (new CEO Junyi Dai) and a reassessment of development priorities are underway.
  • All outstanding Series AA and AAA preferred stock converted into common stock during Q1 2026.
  • The company paused enrollment in its Phase 1 combination study pending further evaluation.

Financial Impact

Cash burn of $7.0M in Q1 2026 left only $1.5M, implying less than one quarter of runway without additional funding.

cashcash flowfunding runway

Risk Factors

  • Going concern risk if additional financing is not secured within months.
  • Severe dilution from any equity or convertible financing.
  • Potential Nasdaq delisting if market cap or bid price falls below thresholds.
  • Clinical pipeline uncertainty: the Phase 1 trial is paused and development priorities are being reassessed.
  • Management transition adds execution risk.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-023344
Document: form8-k.htm0001493152-26-023344
Document: 0001493152-26-023344-index-headers.html0001493152-26-023344
Document: 0001493152-26-023344-index.html0001493152-26-023344
Document: 0001493152-26-023344.txt0001493152-26-023344
8-K Data (Synthetic)0001493152-26-023344

Track record

20 reports on INDP

Performance horizon

4 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +59.35% at T+20 after the Jul 20, 2026 report. 6 of 10 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.17 Now $3.45 +8.83% settles Dec 15
  2. Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  3. Oct 22, 202625d ago SC 13D/A Neutral 3/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  4. Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  5. Oct 21, 202626d ago SC 13D/A Neutral 4/10 Entry $2.99 Now $3.45 +15.38% settles Nov 19
  6. Oct 20, 202627d ago 8-K Bearish 6/10 Entry $3.16 Now $3.45 −9.18% settles Nov 18
  7. Sep 30, 20266w ago 8-K Neutral 3/10 Entry $2.30 to $3.31 Now $3.45 +50.00% ▲ +43.70% +42.43% vs SPY
  8. Sep 9, 20269w ago 8-K Bearish 7/10 Entry $2.56 to $2.37 Now $3.45 −34.77% ▲ +7.42% +9.55% vs SPY
  9. Sep 4, 202610w ago 424B5 Bearish 6/10 Entry $1.85 to $2.59 Now $3.45 −86.49% ▼ −40.00% −38.29% vs SPY
  10. Sep 1, 202610w ago 8-K Bearish 5/10 Entry $1.13 to $2.32 Now $3.45 −205.31% ▼ −104.87% −103.69% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 15, 2026